Gufic Biosciences Limited has announced that its board meeting is scheduled to be held on Friday, May 29, 2026. The meeting will be conducted pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agenda for the Meeting

The primary agenda for the board meeting includes the consideration and approval of the audited financial results for the company. These results will cover both standalone and consolidated figures for the quarter and financial year ended March 31, 2026.

Additionally, the board will deliberate on recommending a final dividend on equity shares for the financial year 2025-26. Any dividend declared will be subject to the approval of shareholders at the ensuing Annual General Meeting.

Trading Window Closure

In continuation of the disclosure regarding the closure of the trading window dated March 27, 2026, the company has stated that the trading window shall remain closed. This restriction applies to all designated persons of the company along with their immediate relatives.

The closure is in accordance with the company's Code of Conduct for Prevention of Insider Trading, framed under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut until 48 hours after the declaration of the financial results.

Gufic Biosciences has completed a further investment of USD 50,000 in Selvax Pty Ltd through subscription of 378,350 ordinary shares at AUD 0.20 per share on April 28, 2026. The company informed stock exchanges BSE and NSE about this strategic investment under Regulation 30 of SEBI Listing Regulations on April 29, 2026.

Investment Transaction Details

The investment was executed through cash consideration, marking the company's continued expansion into the biotechnology sector. This transaction follows an earlier intimation dated February 13, 2026, regarding the company's investment plans in Selvax.

About Selvax Pty Ltd

Selvax Pty Limited is an Australian proprietary company incorporated on August 14, 1987, engaged in biopharma research and development. The company specializes in developing novel immunology-based treatments for large solid tumours, with technology fully owned by Selvax. The therapy aims to provide innovative cancer treatments for both animals and humans, with potential applications across various solid tumours including sarcomas, lung cancer, pancreatic, skin, breast, and colorectal cancer.

Financial Performance and Background

Selvax has demonstrated consistent revenue growth over the past three financial years. The total issued share capital of Selvax as of June 30, 2025, stands at AUD 52,85,176.

Strategic Rationale and Regulatory Compliance

The acquisition represents a strategic arrangement for developing immunotherapy solutions in oncology, enabling Gufic Biosciences to diversify into healthcare and biotechnology sectors. The investment provides access to proprietary technology, research capabilities, and potential commercial opportunities in both human and veterinary oncology. The company confirmed that this transaction does not fall within related party transactions, and promoter groups have no interest in Selvax. No governmental or regulatory approvals were required for this acquisition, and the transaction has been completed as reported to the exchanges.